RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $89 and keeps an Outperform rating on the shares. The company delivered a Q3 sales and earnings upside surprise of 4%/12%, driven by TAVR outperformance and TMTT/surgery beats, the analyst tells investors in a research note. Sentiment on Edwards Lifesciences has shifted positively of late post TCT updates and Q3 print as several of its catalysts take hold for a multi-year runway, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $90 from $85 at JPMorgan
- Edwards Lifesciences price target raised to $83 from $81 at Baird
- Edwards Lifesciences price target raised to $100 from $90 at Mizuho
- Edwards Lifesciences price target raised to $95 from $90 at Piper Sandler
- Edwards Lifesciences price target raised to $96 from $95 at Citi